Patented small molecule therapeutics that target cancer stem cells for the treatment of glioblastoma and other brain cancers

Informations projet

Curtana

N° de convention de subvention: 762351

DOI

10.3030/762351

Projet clôturé

Date de signature de la CE 31 Janvier 2017

Date de début 1 Février 2017

Date de fin 31 Mai 2017

Financé au titre de

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coût total

€ 71 429,00

Contribution de l’UE

€ 50 000,00

Coordonné par

CURTANA PHARMA LTD
United Kingdom

Periodic Reporting for period 1 - Curtana (Patented small molecule therapeutics that target cancer stem cells for the treatment of glioblastoma and other brain cancers)

Période du rapport: 2017-02-01 au 2017-05-31

Résumé du contexte et des objectifs généraux du projet

Glioblastoma (GBM) is the most aggressive cancer of the brain and the second most common after meningioma. Approximately 3.19 in 100,000 people develop the disease per year. Based on the incidence rate, it is estimated that 23,700 people will develop GBM in Europe in 2017. The average age of onset is around 64 years old. Typically, treatment of GBM includes surgery followed by chemotherapy and radiation therapy. Because GBM cells are infiltrative throughout the brain and not all cancer cells are removed by the surgery or killed by the chemotherapy and radiation, most people with GBM later develop recurrent disease. The median survival time is approximately 15 months and the 5-year survival rate is less than 10%. Curtana has developed CT-179, an adjuvant to standard of care therapy in the treatment of GBM and other brain cancers. CT-179 directly targets Olig2, a transcription factor expressed in GBM that drives tumour growth and resistance to radiation therapy. Olig2 is not found in healthy brain cells and normal tissues outside the central nervous system (CNS), which means that CT-179 will be far less toxic compared to conventional cancer drugs. In addition to killing the GBM cancer cells, CT-179 makes the radiation therapy more effective and limits the cancer’s ability to invade into healthy tissue. In animal models, CT-179 has been shown to significantly improve survival times. When combined with the current standard of care therapies, CT-179 dramatically delays or prevents tumour growth. The key objectives of the innovation project are to advance CT-179 through a Phase I clinical trial to determine the maximum safe and well-tolerated dose when used in combination with standard of care therapies and measure drug concentrations in the tumour.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

Curtana undertook a full analysis of the both the technical and business potential of CT-179. Curtana reviewed results from the preclinical trials and defined the remaining preclinical activities to be completed prior to in-human trials. Curtana also performed detailed market analysis to effectively size the number of patients in Europe and their reachable market. Curtana also reviewed their approach to later stage drug development and determined two different possible strategies. Curtana also performed a detailed assessment of potential CRO partners selecting the most suitable for the management of Phase I clinical trials.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

The expected outcome of the project is to perform the Phase I clinical trial and determine MTD and drug concentration levels within the tumour. The results will then be utilised to gain further investment and advance the development of the drug. The CT-179 development will boost economic growth and create jobs within Curtana and on a wider scale with CMOs and CROs in Europe.

GBM Treatment